The S&P 500 Index ($SPX) (SPY) is up +1.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +1.09%, and the Nasdaq 100 ...

Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.75%, and the Nasdaq 100 Index ($IUXX) ...

High heat can impact anyone’s health, but new research shows people experiencing homelessness face increased risk.

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

The deal comes at a time when Sage’s stock has demonstrated strong momentum, with InvestingPro data showing a 35% return in just the past week and a 68% year-to-date price return.

The stock rallied after the company announced that Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics through a tender offer of $8.50 per share in cash, totaling around $561 million.

Sage Therapeutics SAGE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below ... estimate of $8.50.

according to InvestingPro data. The price target adjustment follows Sage’s disclosure that Supernus Pharmaceuticals (NASDAQ:SUPN) has made an all-cash offer to acquire the company at $8.50 per ...

Sage Therapeutics SAGE announced that Supernus Pharmaceuticals SUPN has agreed to acquire SAGE through a tender offer of $8.50 per share in cash, totaling around $561 million. Additionally ...

The programming language SQL hit 12th place in the TIOBE Programming Community Index, its lowest position since the rankings ...